Plain-English translation of NCT04502394 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of two oral medications— and —to treat two types of blood cancers that have come back or stopped responding to previous treatments: diffuse large B-cell lymphoma and chronic lymphocytic leukemia. Both medications work by targeting different pathways in cancer cells. The study wants to see if giving them together is safe and effective.
Many patients with these blood cancers eventually stop responding to standard treatments, leaving them with limited options. This medication combination targets cancer cells in a new way, and researchers hope it may help patients whose cancers have become resistant to other therapies.
You likely qualify if…
You likely don't qualify if…
You would take one medication by mouth once daily for 7 days each month, and a second medication twice daily every day. The study lasts for multiple months as researchers monitor how well the treatment works and track any side effects through regular blood tests and clinic visits. You will be part of a group of up to 84 patients with similar cancers, helping researchers understand whether this medication combination is safe and effective.
AI-generated summary from trial data · Sep 1, 2026 · Not medical advice
United States
Australia